INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 45h ago
HOUSE PTR5h ago
SEC 13F5h ago
ROBINHOOD CHAIN5h ago
Corporate insider
HP

Heerma Peter

CHIEF COMMERCIAL OFFICERCIK 0001789617

EDGAR filingsOpen in network
Disclosed transactions7
Buys / sells0 / 3
Max Insider Score38
Connections1with evidence

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
5
HP
Heerma PeterCHIEF COMMERCIAL OFFICER
TVTXTravere Therapeutics, Inc.
Grant or award
A—
8,500 sh
May 4, 2026May 6, 2026
traded May 4, 2026
+2dSEC FORM 4

Evidence

Verified connections

  • Insider ofevidence
    Travere Therapeutics, Inc.CHIEF COMMERCIAL OFFICER · Dec 29, 2025
35
HP
Heerma PeterCHIEF COMMERCIAL OFFICER
TVTXTravere Therapeutics, Inc.
Open-market sale
SELL
$101K
2,174 sh
May 5, 2026
May 6, 2026
traded May 5, 2026
+1d
SEC FORM 4

Evidence

5
HP
Heerma PeterCHIEF COMMERCIAL OFFICER
TVTXTravere Therapeutics, Inc.
Option exercise
M—
4,250 sh
May 4, 2026May 6, 2026
traded May 4, 2026
+2dSEC FORM 4

Evidence

5
HP
Heerma PeterCHIEF COMMERCIAL OFFICER
TVTXTravere Therapeutics, Inc.
Option exercise
M—
4,250 sh
May 4, 2026May 6, 2026
traded May 4, 2026
+2dSEC FORM 4

Evidence

9
HP
Heerma PeterCHIEF COMMERCIAL OFFICER
TVTXTravere Therapeutics, Inc.
Grant or award
A—
14.0K sh
Apr 13, 2026Apr 15, 2026
traded Apr 13, 2026
+2dSEC FORM 4

Evidence

38
HP
Heerma PeterCHIEF COMMERCIAL OFFICER
TVTXTravere Therapeutics, Inc.
Open-market sale
SELL$303K
7,215 sh
Apr 14, 2026Apr 15, 2026
traded Apr 14, 2026
+1dSEC FORM 4

Evidence

29
HP
Heerma PeterCHIEF COMMERCIAL OFFICER
TVTXTravere Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$199K
4,980 sh
Dec 24, 2025Dec 29, 2025
traded Dec 24, 2025
+5dSEC FORM 4

Evidence